According to a study published by Oxford University on Thursday, the risk of developing rare blood clots is higher for people who contract COVID-19 than for those who are vaccinated.
You are ten times more likely to suffer from cerebral venous sinus thrombosis – the condition that led federal health officials to stop using the Johnson & Johnson vaccine this week after being infected with the coronavirus than it is you got a shot. according to the study.
‘[Findings] should be considered when considering the balance between risks and benefits for vaccination, ‘Paul Harrison, head of Oxford’s Translational Neurobiology Group, told a news conference on Thursday.
During the study, which was used to develop the AstraZeneca vaccine in Europe, researchers looked at the number of coagulation cases in the two weeks after a COVID-19 diagnosis.
They also investigated how many people suffered from the condition two weeks after a single dose of Pfizer, Moderna and AstraZeneca vaccines were administered.
Researchers found that the risk of developing the condition was ten times higher after receiving COVID-19 than after receiving the Pfizer or Moderna shots, and eight times higher after receiving the AstraZeneca jab.
The study does not contain any data on the Johnson & Johnson vaccine, which was discontinued by federal health officials on Tuesday after six women reported suffering from the clotting condition, including a 45-year-old who died.
Like the Johnson & Johnson vaccine in the US, AstraZeneca’s sample came under fire due to possible links with blood clotting in the brain in Europe.
Denmark has stopped using AstraZeneca after an investigation by health officials showed ‘real and serious side effects’. Other countries have restricted the use of the vaccine to older age groups, who are apparently less affected by the blood clots.